Opus Genetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Opus Genetics (Nasdaq: IRD), a clinical-stage ophthalmic biopharmaceutical company, has announced the approval of equity awards as inducement grants to two new employees by its Board's independent members. The awards, approved under the Company's 2021 Inducement Plan and in accordance with Nasdaq Listing rule 635(c)(4), consist of options to purchase 205,742 shares of common stock.
The options were granted on March 13, 2025, with an exercise price of $0.93 per share, matching the closing price on the grant date. The vesting schedule spans four years, with 25% vesting after the first year and the remaining 75% vesting in monthly or quarterly installments thereafter, subject to certain acceleration or forfeiture conditions.
Opus Genetics (Nasdaq: IRD), un'azienda biofarmaceutica oftalmica in fase clinica, ha annunciato l'approvazione di premi azionari come incentivi per due nuovi dipendenti da parte dei membri indipendenti del Consiglio. I premi, approvati nell'ambito del Piano di Incentivazione 2021 della Società e in conformità con la regola di quotazione Nasdaq 635(c)(4), consistono in opzioni per acquistare 205.742 azioni di azioni ordinarie.
Le opzioni sono state concesse il 13 marzo 2025, con un prezzo di esercizio di 0,93 $ per azione, corrispondente al prezzo di chiusura nella data di concessione. Il piano di maturazione si estende per quattro anni, con un 25% che matura dopo il primo anno e il restante 75% che matura in rate mensili o trimestrali successivamente, soggetto a determinate condizioni di accelerazione o di perdita.
Opus Genetics (Nasdaq: IRD), una empresa biofarmacéutica oftálmica en etapa clínica, ha anunciado la aprobación de premios de acciones como incentivos para dos nuevos empleados por parte de los miembros independientes de su Junta. Los premios, aprobados bajo el Plan de Incentivos 2021 de la Compañía y de acuerdo con la regla de cotización 635(c)(4) de Nasdaq, consisten en opciones para comprar 205,742 acciones de acciones ordinarias.
Las opciones se otorgaron el 13 de marzo de 2025, con un precio de ejercicio de $0.93 por acción, igualando el precio de cierre en la fecha de concesión. El calendario de adquisición se extiende por cuatro años, con un 25% que se adquiere después del primer año y el restante 75% que se adquiere en cuotas mensuales o trimestrales posteriormente, sujeto a ciertas condiciones de aceleración o pérdida.
Opus Genetics (Nasdaq: IRD)는 임상 단계의 안과 생명공학 회사로, 이사회의 독립적인 구성원에 의해 두 명의 신입 직원에게 유인 보상으로서 주식 보상을 승인했다고 발표했습니다. 이 보상은 회사의 2021년 유인 계획에 따라 승인되었으며, Nasdaq 상장 규칙 635(c)(4)에 따라 205,742주의 보통주를 구매할 수 있는 옵션으로 구성됩니다.
옵션은 2025년 3월 13일에 부여되었으며, 행사 가격은 주당 $0.93로, 부여일의 종가와 일치합니다. 권리 확정 일정은 4년으로, 첫 해에 25%가 확정되며, 나머지 75%는 이후 매월 또는 분기별 할부로 확정되며, 특정 가속 또는 몰수 조건에 따라 달라질 수 있습니다.
Opus Genetics (Nasdaq: IRD), une entreprise biopharmaceutique ophtalmique en phase clinique, a annoncé l'approbation de récompenses en actions comme incitations pour deux nouveaux employés par les membres indépendants de son conseil d'administration. Les récompenses, approuvées dans le cadre du Plan d'Incitation 2021 de l'entreprise et conformément à la règle de cotation 635(c)(4) de Nasdaq, consistent en des options d'achat de 205 742 actions ordinaires.
Les options ont été accordées le 13 mars 2025, avec un prix d'exercice de 0,93 $ par action, correspondant au prix de clôture à la date d'octroi. Le calendrier d'acquisition s'étend sur quatre ans, avec un 25% qui acquiert des droits après la première année et les 75% restants qui acquièrent des droits en versements mensuels ou trimestriels par la suite, sous réserve de certaines conditions d'accélération ou de perte.
Opus Genetics (Nasdaq: IRD), ein biopharmazeutisches Unternehmen im klinischen Stadium, hat die Genehmigung von Aktienvergütungen als Anreiz für zwei neue Mitarbeiter durch die unabhängigen Mitglieder des Vorstands bekannt gegeben. Die unter dem Incentive-Plan 2021 des Unternehmens genehmigten Vergütungen bestehen aus Optionen zum Kauf von 205.742 Aktien des Stammkapitals.
Die Optionen wurden am 13. März 2025 gewährt, mit einem Ausübungspreis von 0,93 $ pro Aktie, der dem Schlusskurs am Tag der Gewährung entspricht. Der Vesting-Zeitraum erstreckt sich über vier Jahre, wobei 25% nach dem ersten Jahr und die verbleibenden 75% anschließend in monatlichen oder vierteljährlichen Raten fällig werden, vorbehaltlich bestimmter Beschleunigungs- oder Verfallbedingungen.
- None.
- None.
RESEARCH TRIANGLE PARK, N.C., March 19, 2025 (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (Nasdaq: IRD), a clinical-stage ophthalmic biopharmaceutical company developing important new therapies for the treatment of inherited retinal diseases (IRDs) and other ophthalmic disorders (“Opus” or the “Company”), today announced that the independent members of its Board of Directors approved equity awards under the Company’s 2021 Inducement Plan, as amended, as a material inducement to two new employees in connection with the commencement of their employment with the Company effective March 13, 2025. The equity awards were approved in accordance with Nasdaq Listing rule 635(c)(4), which also requires a public announcement of equity awards that are not made under a stockholder approved equity plan.
The equity awards were granted in the form of options to purchase an aggregate of 205,742 shares of the Company’s common stock. The option awards each have an exercise price of
About Opus Genetics
Opus Genetics is a clinical-stage ophthalmic biopharmaceutical company developing therapies to treat patients with inherited retinal diseases (IRDs) and other treatments for ophthalmic disorders. Our pipeline includes adeno-associated virus (AAV)-based investigational gene therapies that address mutations in genes that cause different forms of bestrophinopathy, Leber congenital amaurosis (LCA) and retinitis pigmentosa. Our most advanced investigational gene therapy program is designed to address mutations in the LCA5 gene, which encodes the lebercilin protein and is currently being evaluated in a Phase 1/2 open-label, dose-escalation trial, with encouraging early data. Our pipeline also includes BEST1 investigational gene therapy, designed to address mutations in the BEST1 gene, which is associated with retinal degeneration. The pipeline also includes Phentolamine Ophthalmic Solution
Contacts
| Corporate | Investor Relations |
| Nirav Jhaveri CFO ir@opusgtx.com | Corey Davis, Ph.D. LifeSci Advisors cdavis@lifesciadvisors.com |
FAQ
What is the exercise price for Opus Genetics (IRD) inducement stock options granted in March 2025?
How many shares are included in Opus Genetics' (IRD) March 2025 inducement grants?
What is the vesting schedule for Opus Genetics' (IRD) March 2025 inducement stock options?
Under which plan were Opus Genetics' (IRD) March 2025 inducement grants approved?
